• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

血栓素A2受体拮抗剂的动力学分析。存在摄取系统的证据。

Kinetic analysis of a TxA2 receptor antagonist. Evidence for the existence of an uptake system.

作者信息

Modesti P A, Abbate R, Gensini G F, Colella A, Serneri G G

机构信息

Clinica Medica I, University of Florence, Florence, Italy.

出版信息

Eicosanoids. 1990;3(3):139-43.

PMID:2146970
Abstract

The kinetics of the binding of TxA2 and the characteristics of its putative uptake by platelets (plt) were investigated with a radiolabelled structural TxA2 analogue, 125I-PTA-OH, in platelets from 6 male healthy volunteers. The kinetic constants (Kobs, K1 and K-1) were calculated by time-course experiments according to Weiland and Molinoff. The affinity constant (Km) and maximal uptake velocity (Vmax) values for each subject were determined by the double-reciprocal plot of Lineweaver-Burk. The kinetically determined dissociation constant Kd was 10 nmol/l. In the uptake experiments a saturability of the association rate of the non-displaceable binding was observed at increased ligand concentration. Michaelis-Menten type kinetics were obtained and the Vmax was 32.44 fmol/10(8) plt x hour with a Km of 6.39 nmol/l. These observations suggest that the uptake was a carrier-mediated active transport.

摘要

利用放射性标记的血栓素A2(TxA2)结构类似物125I-PTA-OH,对6名男性健康志愿者血小板中TxA2的结合动力学及其假定的摄取特性进行了研究。根据韦兰德和莫利诺夫的方法,通过时间进程实验计算动力学常数(Kobs、K1和K-1)。通过Lineweaver-Burk双倒数图确定每个受试者的亲和常数(Km)和最大摄取速度(Vmax)值。动力学测定的解离常数Kd为10 nmol/l。在摄取实验中,在配体浓度增加时观察到不可置换结合的缔合速率具有饱和性。获得了米氏动力学类型,Vmax为32.44 fmol/10(8) 血小板×小时,Km为6.39 nmol/l。这些观察结果表明摄取是一种载体介导的主动转运。

相似文献

1
Kinetic analysis of a TxA2 receptor antagonist. Evidence for the existence of an uptake system.血栓素A2受体拮抗剂的动力学分析。存在摄取系统的证据。
Eicosanoids. 1990;3(3):139-43.
2
Binding of an 125I-labeled thromboxane A2/prostaglandin H2 receptor antagonist to washed canine platelets.125I标记的血栓素A2/前列腺素H2受体拮抗剂与洗涤过的犬血小板的结合。
Mol Pharmacol. 1985 Aug;28(2):163-9.
3
Binding of a thromboxane A2/prostaglandin H2 receptor antagonist to washed human platelets.血栓素A2/前列腺素H2受体拮抗剂与洗涤过的人血小板的结合
J Pharmacol Exp Ther. 1985 Dec;235(3):729-34.
4
Hemorrhagic thrombocytopathy with platelet thromboxane A2 receptor abnormality: defective signal transduction with normal binding activity.伴有血小板血栓素A2受体异常的出血性血小板病:结合活性正常但信号转导缺陷。
Thromb Haemost. 1987 Apr 7;57(2):158-64.
5
Identification of a putative thromboxane A2/prostaglandin H2 receptor in human platelet membranes.人血小板膜中一种假定的血栓素A2/前列腺素H2受体的鉴定。
J Biol Chem. 1986 Mar 5;261(7):3025-9.
6
Platelet and vascular smooth muscle thromboxane A2/prostaglandin H2 receptors.血小板与血管平滑肌血栓素A2/前列腺素H2受体
Fed Proc. 1987 Jan;46(1):149-53.
7
Solubilization of a thromboxane A2/prostaglandin H2 antagonist binding site from human platelets.人血小板中血栓素A2/前列腺素H2拮抗剂结合位点的增溶作用
Proc Natl Acad Sci U S A. 1985 Nov;82(21):7434-8. doi: 10.1073/pnas.82.21.7434.
8
Human erythroleukemia cells express functional thromboxane A2/prostaglandin H2 receptors.
J Pharmacol Exp Ther. 1989 Sep;250(3):923-7.
9
Pharmacologic characterization of human and canine thromboxane A2/prostaglandin H2 receptors in platelets and blood vessels: evidence for different receptors.人和犬血小板及血管中血栓素A2/前列腺素H2受体的药理学特性:不同受体的证据
J Pharmacol Exp Ther. 1985 May;233(2):418-24.
10
Photoaffinity labelling and isoelectric focusing of the human platelet thromboxane A2/prostaglandin H2 (TXA2/PGH2) receptor.
Adv Prostaglandin Thromboxane Leukot Res. 1989;19:168-71.

引用本文的文献

1
Binding kinetics and antiplatelet activities of picotamide, a thromboxane A2 receptor antagonist.血栓素A2受体拮抗剂匹可托安的结合动力学及抗血小板活性
Br J Pharmacol. 1994 May;112(1):81-6. doi: 10.1111/j.1476-5381.1994.tb13033.x.
2
Acute reduction of TxA2 platelet binding sites after in vivo administration of a TxA2 receptor inhibitor.体内给予血栓素A2(TxA2)受体抑制剂后,TxA2血小板结合位点的急性减少。
Br J Clin Pharmacol. 1991 Apr;31(4):439-43. doi: 10.1111/j.1365-2125.1991.tb05560.x.